4DMT加速溼性AMD的4FRONT第三階段項目，實施裁員措施4DMT Accelerates 4FRONT Phase 3 Program for Wet AMD, Implements Workforce Reduction

動脈網

2025/07/08

4DMT Accelerates 4FRONT Phase 3 Program for Wet AMD, Implements Workforce Reduction4DMT加速溼性AMD的4FRONT第三階段項目，實施裁員措施July 08, 20252025年7月8日4D Molecular Therapeutics (4DMT) has announced the acceleration ...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2549546558"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2549546558\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2549546558?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-08 18:29","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2549546558","market":"us","top_or_hot":-1,"title":"4DMT加速溼性AMD的4FRONT第三階段項目，實施裁員措施4DMT Accelerates 4FRONT Phase 3 Program for Wet AMD, Implements Workforce Reduction","media":"動脈網","content":"<div>\n<p>4DMT Accelerates 4FRONT Phase 3 Program for Wet AMD, Implements Workforce Reduction4DMT加速溼性AMD的4FRONT第三階段項目，實施裁員措施July 08, 20252025年7月8日4D Molecular Therapeutics (4DMT) has announced the acceleration ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708183324953ab7a8&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4DMT加速溼性AMD的4FRONT第三階段項目，實施裁員措施4DMT Accelerates 4FRONT Phase 3 Program for Wet AMD, Implements Workforce Reduction</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4DMT加速溼性AMD的4FRONT第三階段項目，實施裁員措施4DMT Accelerates 4FRONT Phase 3 Program for Wet AMD, Implements Workforce Reduction\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">動脈網</strong><span class=\"h-time small\">2025-07-08 18:29</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>4DMT Accelerates 4FRONT Phase 3 Program for Wet AMD, Implements Workforce Reduction4DMT加速溼性AMD的4FRONT第三階段項目，實施裁員措施July 08, 20252025年7月8日4D Molecular Therapeutics (4DMT) has announced the acceleration ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708183324953ab7a8&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708183324953ab7a8&s=b\">動脈網</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0719512351.SGD","symbol_name":"JPMorgan Funds - US Technology A (acc) SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708183324953ab7a8&s=b","article_id":"2549546558","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708183324953ab7a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2549546558","pubTimestamp":1751970540,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"Additionally, 4FRONT-2, the global phase 3 trial of 4D-150 in wet AMD, was initiated in June 2025 ahead of schedule. This study mirrors the design of 4FRONT-1 but will enroll both treatment-nave patients and recently diagnosed, treatment-experienced individuals. Topline results from 4FRONT-2 are expected in the second half of 2027..此外，4D-150用於濕性AMD的全球三期試驗4FRONT-2已於2025年6月提前啓動。4FRONT-2的初步結果預計將在2027年下半年公布。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","BK4588":"碎股","LU1803068979.SGD":"FTIF - Franklin Technology A (acc) SGD-H1","BK4605":"半导体精选","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","BK4614":"Manus概念股","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","AMD":"美国超微公司","BK4573":"虚拟现实","BK4554":"元宇宙及AR概念","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","BK4532":"文艺复兴科技持仓","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","BK4543":"AI","LU0823421333.USD":"BNP PARIBAS DISRUPTIVE TECHNOLOGY \"C\" (USD) ACC","LU2054465674.USD":"UBS (LUX) KEY SELEC SICAV DIGITAL TRANSFORMATION T \"P\" (USD) ACC","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU0056508442.USD":"贝莱德世界科技基金A2","LU1303367103.USD":"摩根大通多经理另类基金 A (acc)","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","BK4534":"瑞士信贷持仓","BK4141":"半导体产品","LU0823421416.USD":"BNP PARIBAS DISRUPTIVE TECHNOLOGY \"C\" (USD) INC","LU2098885051.SGD":"JPMorgan Funds - Multi-Manager Alternatives A (acc) SGD","GFS":"GLOBALFOUNDRIES Inc.","BK4529":"IDC概念","LU2458330169.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A\" (SGD) ACC","BK4575":"芯片概念","LU1880398471.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) ACC","BK4566":"资本集团","LU2458330243.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A-H1\" (SGDHDG) ACC","LU0109392836.USD":"富兰克林科技股A","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","IE00B5949003.HKD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A\" (HKD) ACC","LU0642271901.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD-H","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","BK4612":"AI芯片","LU2360106780.USD":"BGF WORLD TECHNOLOGY \"A4\" (USD) INC","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","LU0082616367.USD":"摩根大通美国科技A（dist）","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC"},"translate_title":"4DMT Accelerates 4FRONT Phase 3 Project for Wet AMD, Implements Layoff Measures 4DMT Accelerates 4FRONT Phase 3 Program for Wet AMD, Implements Workforce Reduction","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GFS":1,"AMD":0.9},"content_text":"4DMT Accelerates 4FRONT Phase 3 Program for Wet AMD, Implements Workforce Reduction4DMT加速濕性AMD的4FRONT第三階段項目，實施裁員措施July 08, 20252025年7月8日4D Molecular Therapeutics (4DMT) has announced the acceleration of its 4D-150 4FRONT phase 3 clinical program targeting wet age-related macular degeneration (wet AMD) alongside a strategic move to lay off approximately 25% of its workforce. This decision comes as the company sharpens its focus on advancing its late-stage pipeline..4D Molecular Therapeutics (4DMT) 宣佈加速其針對濕性年齡相關性黃斑變性（濕性AMD）的4D-150 4FRONT第三階段臨床計劃，同時進行戰略調整，裁員約25%的員工。這一決定是在公司集中精力推進其後期管線之際作出的。Streamlining Operations to Support Accelerated Timelines簡化操作以支持加快的時間表According to 4DMT, the company will streamline operations to help offset additional costs tied to the faster timelines of the 4FRONT clinical trials and biologics license application (BLA) preparation. This transition aligns with the strategy first announced in January 2025, emphasizing a focus on late-stage programs.根據4DMT公司介紹，公司將精簡運營，以幫助抵消與4FRONT臨床試驗和生物製品許可申請（BLA）準備加快時間表相關的額外成本。此次轉型符合公司於2025年1月首次宣佈的戰略，重點放在後期項目上。At that time, 4DMT shared plans to discontinue early-stage rare disease programs evaluating 4D-110 for choroideremia and 4D-125 for X-linked retinitis pigmentosa. The company also indicated it would pause new preclinical investments, projecting that these adjustments would enable it to fund operations into 2028..當時，4DMT分享了計劃，將終止早期罕見病項目，包括針對脈絡膜缺失症評估4D-110和針對X連鎖視網膜色素變性評估4D-125的項目。該公司還表示將暫停新的臨床前投資，預計這些調整將使其能夠為運營提供資金直至2028年。Progress in 4FRONT Phase 3 Trials of 4D-1504D-150在4FRONT第三階段試驗中的進展4DMT highlighted that enrollment and site activation for 4FRONT-1, the North American phase 3 trial of 4D-150 in wet AMD, have surpassed initial expectations. The first patient in 4FRONT-1 was enrolled in March 2025, and topline data are now anticipated in the first half of 2027—earlier than the initial forecast of late 2027..4DMT 強調，濕性 AMD 的 4D-150 北美 III 期試驗 4FRONT-1 的受試者招募和試驗站點啓動已超出最初預期。4FRONT-1 的首例患者於 2025 年 3 月入組，目前預計將在 2027 年上半年獲得初步數據——比最初的 2027 年底預測提前。Additionally, 4FRONT-2, the global phase 3 trial of 4D-150 in wet AMD, was initiated in June 2025 ahead of schedule. This study mirrors the design of 4FRONT-1 but will enroll both treatment-naïve patients and recently diagnosed, treatment-experienced individuals. Topline results from 4FRONT-2 are expected in the second half of 2027..此外，4D-150用於濕性AMD的全球三期試驗4FRONT-2已於2025年6月提前啓動。該研究的設計與4FRONT-1相似，但將同時納入未曾接受治療的患者和近期確診、有治療經驗的人士。4FRONT-2的初步結果預計將在2027年下半年公布。Workforce Reduction to Offset Costs and Reallocate Resources裁員以抵消成本並重新分配資源As part of its operational transition, 4DMT plans to reduce its workforce by approximately 25% in July 2025, primarily impacting early-stage research, development, and related support functions. This reduction is expected to deliver about $15 million in annual cash compensation cost savings, helping offset increased expenses from the accelerated phase 3 timelines and BLA work..作為其運營過渡的一部分，4DMT 計劃在 2025 年 7 月裁員約 25%，主要影響早期研究、開發及相關支持職能。此次裁員預計每年可節省約 1500 萬美元的現金薪酬成本，有助於抵消因加速第三階段時間表和 BLA 工作帶來的支出增加。Leadership Comments on Strategic Shift領導層對戰略轉變的評論David Kirn, MD, co-founder and CEO, and Dhaval Desai, chief development officer of 4DMT, shared insights into the company’s direction in a press release.4DMT聯合創始人兼首席執行官David Kirn醫學博士以及首席開發官Dhaval Desai在新聞稿中分享了公司發展方向的見解。「We are thrilled with the strong interest in 4D-150 from investigators and patients in both 4FRONT phase 3 studies, reflecting their belief in the phase 1/2 data demonstrating the tolerability and robust, durable clinical activity of this potential foundational backbone therapy for retinal vascular diseases,」 said Desai..「我們對4D-150在兩項4FRONT三期研究中引起的研究者和患者的濃厚興趣感到非常興奮，這反映了他們對一期/二期數據的信任，這些數據展示了這種潛在的基礎骨幹療法在視網膜血管疾病中的耐受性以及強大且持久的臨床活性，」Desai表示。Kirn added, 「We have aligned our resources to deliver on our mission of bringing transformative and durable genetic medicines to millions of patients in need, with a focus on 4D-150 for wet AMD, in our ongoing transition to becoming a commercial company. I want to express my deep gratitude and respect for the talented colleagues whose work has been critical to 4DMT’s success to date, who we thank sincerely for their dedication to and passion for our mission.」.柯恩補充道：「我們已經整合了資源，以實現我們為數百萬有需要的患者提供變革性且持久的基因藥物的使命，並在我們向商業化公司轉型的過程中，重點關注用於濕性AMD的4D-150。我要對我們才華橫溢的同事們表達深深的感激與敬意，他們的工作對4DMT迄今為止的成功至關重要，我們衷心感謝他們對我們的使命所付出的奉獻和熱情。」","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}